Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

93.47USD
1:30am IST
Change (% chg)

$-5.44 (-5.50%)
Prev Close
$98.91
Open
$95.63
Day's High
$95.75
Day's Low
$93.47
Volume
2,765,920
Avg. Vol
2,051,343
52-wk High
$98.97
52-wk Low
$58.61

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $69,757.22
Shares Outstanding(Mil.): 705.26
Dividend: --
Yield (%): --

Financials

  CELG.OQ Industry Sector
P/E (TTM): 15.18 32.50 37.40
EPS (TTM): 6.52 -- --
ROI: 14.44 12.49 12.12
ROE: 70.51 13.80 17.02

Deals of the day-Mergers and acquisitions

June 24 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

1:32am IST

Wall St. flat as healthcare losses limit tech gains

Wall Street's main indexes were flat on Monday, as losses in healthcare stocks offset gains in the technology sector, while investors awaited a high-stakes meeting between U.S. and Chinese leaders at the G20 summit later this week.

24 Jun 2019

US STOCKS-Wall St flat as healthcare losses limit tech gains

* Dow up 0.17%, S&P flat, Nasdaq off 0.04% (Updates to early afternoon)

24 Jun 2019

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

24 Jun 2019

UPDATE 3-Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide

June 24 Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion deal.

24 Jun 2019

US STOCKS-Wall St edges higher as tech gains more than offset healthcare losses

* Indexes up: Dow 0.19%, S&P 0.10%, Nasdaq 0.04% (Updates prices, comments)

24 Jun 2019

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

24 Jun 2019

US STOCKS-Wall Street edges higher as tech offsets healthcare loss

* Dow up 0.23%, S&P rises 0.11%, Nasdaq inches 0.06% higher (Updates to open)

24 Jun 2019

Bristol to divest Celgene's psoriasis treatment in FTC clearance push

June 24 Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).

24 Jun 2019

Investor Ackman opposes United Technologies' aerospace merger with Raytheon - source

Billionaire investor William Ackman's activist hedge fund Pershing Square Capital Management LP is opposing United Technologies Corp's planned $120 billion aerospace merger with defence contractor Raytheon Co, a person familiar with the matter said on Tuesday.

12 Jun 2019

Earnings vs. Estimates